Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543), administered orally once daily in participants with myelofibrosis. The primary hypothesis is that bomedemstat is a safe and tolerable orally available agent when administered to participants with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera-myelofibrosis (PPVMF), and post-essential thrombocythaemia-myelofibrosis (PET-MF) (collectively referred to as 'MF'); inhibition of LSD1 by bomedemstat will reduce spleen size in those with splenomegaly, improve haematopoiesis and reduce constitutional symptoms associated with these disorders.

Additional locations may be listed on ClinicalTrials.gov for NCT03136185.

Trial PhasePhase I/II

Trial Typetreatment

Lead OrganizationImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

• Primary IDIMG-7289-CTP-102
• Secondary IDsNCI-2018-00337, 2018-003811-23, MK-3543-002
• ClinicalTrials.gov IDNCT03136185